Combination immune therapy and cytokine control therapy for cancer treatment

Abstract

Compositions disclosed herein, and methods of use thereof included those for inhibiting or reducing the incidence of cytokine release syndrome or cytokine storm in a subject undergoing CAR T-cell therapy, wherein the subjects are administered compositions comprising apoptotic cells or apoptotic cell supernatants. In certain instances compositions and methods of use thereof disclosed herein do notreduce the efficacy of the CAR T-cell cancer therapy. Disclosed herein are also compositions and methods of use thereof for decreasing or inhibiting cytokine production in a subject experiencing cytokine release syndrome or cytokine storm comprising administration of a composition comprising apoptotic cells or an apoptotic cell supernatant.

Description

technical field [0001] Disclosed herein are compositions and methods thereof for maintaining or increasing the proliferation rate of chimeric antigen receptor expressing T cells during CAR T cell cancer therapy. In addition, disclosed herein are compositions and methods for increasing the efficacy of chimeric antigen receptor T cell cancer therapy, wherein the incidence of a subject experiencing cytokine release syndrome or cytokine storm is reduced or inhibited. The method disclosed herein includes: a method comprising administering CAR T cells and an additional agent, the additional agent comprising apoptotic cells, apoptotic cell supernatant, CTLA-4 blocking agent, α-1 antitrypsin or a fragment thereof or analogs, tellurium-based compounds or immunomodulators, or any combination thereof. Background technique [0002] While the standard treatments for cancer are surgery, chemotherapy and radiation therapy, improved approaches, such as targeted immunotherapy, are currently...

AI Technical Summary

Problems solved by technology

If CAR-targeted tumor-associated antigens are expressed in normal tissues, as no

Images